552. Evaluation of Relationships Between UGT1A1 Genotypes and Cabotegravir Long-Acting Injection Pharmacokinetics Among HIV-Infected Subjects in the LATTE-2 Study

BACKGROUND: Cabotegravir (CAB), an HIV integrase inhibitor primarily metabolized by UGT1A1, is in development as an oral tablet and long-acting (LA) intramuscular (IM) injection for the treatment and prevention of HIV infection. CAB LA has a prolonged absorption phase, typical of flip-flop PK, which...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Zhengyu, King, Karen S, Ford, Susan L, Lou, Yu, Bakshi, Kalpana K, Margolis, David A, Hughes, Arlene R, Spreen, William R, Patel, Parul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255463/
http://dx.doi.org/10.1093/ofid/ofy210.560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255463/
http://dx.doi.org/10.1093/ofid/ofy210.560

Ejemplares similares